Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines

References

• Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, et al. 2007. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 81(9):4654–63.
   PubMed Web of Science ®Google Scholar
• Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, et al. 2020. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med. 383(25):2427–38.
   PubMed Web of Science ®Google Scholar
• Andries O, Mc Cafferty S, De Smedt SC, Weiss R, Sanders NN, Kitada T. 2015. N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. J Control Release. 217:337–44.
   PubMed Web of Science ®Google Scholar
• Appledorn DM, Patial S, McBride A, Godbehere S, Van Rooijen N, Parameswaran N, Amalfitano A. 2008. Adenovirus vector-induced innate inflammatory mediators, MAPK signaling, as well as adaptive immune responses are dependent upon both TLR2 and TLR9 in vivo. J Immunol. 181(3):2134–44.
   PubMed Web of Science ®Google Scholar
• Arvin AM, Fink K, Schmid MA, Cathcart A, Spreafico R, Havenar-Daughton C, Lanzavecchia A, Corti D, Virgin HW. 2020. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 584(7821):353–63.
   PubMed Web of Science ®Google Scholar
• Bachy V, Hervouet C, Becker PD, Chorro L, Carlin LM, Herath S, Papagatsias T, Barbaroux JB, Oh SJ, Benlahrech A, et al. 2013. Langerin negative dendritic cells promote potent CD8+ T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays. Proc Natl Acad Sci U S A. 110(8):3041–46.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. 2020. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 384:2320–2332.
   Web of Science ®Google Scholar
• Baden LR, Walsh SR, Seaman MS, Tucker RP, Krause KH, Patel A, Johnson JA, Kleinjan J, Yanosick KE, Perry J, et al. 2013. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J Infect Dis. 207(2):240–47.
   PubMed Web of Science ®Google Scholar
• Balmert SC, Carey CD, Falo GD, Sethi SK, Erdos G, Korkmaz E, Falo LD Jr. 2020. Dissolving undercut microneedle arrays for multicomponent cutaneous vaccination. J Control Release. 317:336–46.
   Web of Science ®Google Scholar
• Barone E. 2020. The Trump Administration's 'Operation Warp Speed' Has Spent $12.4 Billion on Vaccines. How Much Is That, Really? TIME 2020 December 14, 2020.
   Google Scholar
• Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, et al. 2004. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol. 172(10):6290–97.
   PubMed Web of Science ®Google Scholar
• Behmard E, Soleymani B, Najafi A, Barzegari E. 2020. Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2. Sci Rep. 10(1):20864.
   PubMed Web of Science ®Google Scholar
• BioNtech. 2020. Study to describe the safety, tolerability, immunogenicity, and efficacy of RNA vaccine candidates against COVID-19 in healthy individuals. ClinicalTrialsGov.
   Google Scholar
• Bradley AJ, Brooks DE, Norris-Jones R, Devine DV. 1999. C1q binding to liposomes is surface charge dependent and is inhibited by peptides consisting of residues 14-26 of the human C1qA chain in a sequence independent manner. Biochim Biophys Acta. 1418(1):19–30.
   PubMed Web of Science ®Google Scholar
• Brewer JM. 2006. (How) do aluminium adjuvants work? Immunol Lett. 102(1):10–15.
   PubMed Web of Science ®Google Scholar
• Briuglia ML, Rotella C, McFarlane A, Lamprou DA. 2015. Influence of cholesterol on liposome stability and on in vitro drug release. Drug Deliv Transl Res. 5(3):231–42.
   PubMed Web of Science ®Google Scholar
• Campbell JD. 2017. Development of the CpG adjuvant 1018: a case study. Methods Mol Biol. 1494:15–27.
   PubMedGoogle Scholar
• Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME, Tang A, Chen M, Huang L, Harris V, et al. 2003. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol. 77(11):6305–13.
   PubMed Web of Science ®Google Scholar
• Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Gu L, Martin JE, Novik L, Chakrabarti BK, et al. 2006. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 194(12):1638–49.
   PubMed Web of Science ®Google Scholar
• Chahal JS, Fang T, Woodham AW, Khan OF, Ling J, Anderson DG, Ploegh HL. 2017. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8+ T cell responses in a mouse model. Sci Rep. 7(1):252.
   PubMedGoogle Scholar
• Chen IY, Moriyama M, Chang MF, Ichinohe T. 2019. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol. 10:1050.
   PubMed Web of Science ®Google Scholar
• Chu H, Chan JF, Yuen TT, Shuai H, Yuan S, Wang Y, Hu B, Yip CC, Tsang JO, Huang X, et al. 2020. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe. 1(1):e14–e23.
   PubMedGoogle Scholar
• Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV). 2020. at https://clinicaltrials.gov/ct2/show/NCT04456595?term=NCT04456595&draw=2&rank=1.)
   Google Scholar
• Corbett KS, Edwards D, Leist SR, Abiona OM, Boyoglu-Barnum S, Gillespie RA, Himansu S, Schafer A, Ziwawo CT, DiPiazza AT, et al. 2020. SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen preparedness. Nature. 586(7530): 567–71
   PubMedGoogle Scholar
• Cox F, van der Fits L, Abbink P, Larocca RA, van Huizen E, Saeland E, Verhagen J, Peterson R, Tolboom J, Kaufmann B, et al. 2018. Adenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challenge. PLoS One. 13(8):e0202820.
   PubMed Web of Science ®Google Scholar
• Cox RJ, Pedersen G, Madhun AS, Svindland S, Saevik M, Breakwell L, Hoschler K, Willemsen M, Campitelli L, Nostbakken JK, et al. 2011. Evaluation of a virosomal H5N1 vaccine formulated with matrix M adjuvant in a phase I clinical trial. Vaccine. 29(45):8049–59.
   PubMed Web of Science ®Google Scholar
• Cucinotta D, Vanelli M. 2020. WHO declares COVID-19 a pandemic. Acta Biomed. 91(1):157–60.
   PubMedGoogle Scholar
• Danthinne X, Imperiale MJ. 2000. Production of first generation adenovirus vectors: a review. Gene Ther. 7(20):1707–14.
   PubMed Web of Science ®Google Scholar
• Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AV, Cottingham MG, Kremer EJ. 2012. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS One. 7(7):e40385.
   PubMed Web of Science ®Google Scholar
• Dupuis M, Denis-Mize K, LaBarbara A, Peters W, Charo IF, McDonald DM, Ott G. 2001. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol. 31(10):2910–18.
   PubMed Web of Science ®Google Scholar
• Dupuis M, Murphy TJ, Higgins D, Ugozzoli M, Van Nest G, Ott G, McDonald DM. 1998. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol. 186(1):18–27.
   PubMed Web of Science ®Google Scholar
• Eichinger KM, Kosanovich JL, Gidwani SV, Zomback A, Lipp MA, Perkins TN, Oury TD, Petrovsky N, Marshall CP, Yondola MA, et al. 2020. Prefusion RSV F immunization elicits Th2-mediated lung pathology in mice when formulated with a Th2 (but not a Th1/Th2-balanced) adjuvant despite complete viral protection. Front Immunol. 11:111673.
   Web of Science ®Google Scholar
• Fan X, Cao D, Kong L, Zhang X. 2020. Cryo-EM analysis of the post-fusion structure of the SARS-CoV spike glycoprotein. Nat Commun. 11(1):3618.
   PubMed Web of Science ®Google Scholar
• Fathallah AM, Chiang M, Mishra A, Kumar S, Xue L, Russell Middaugh C, Balu-Iyer SV. 2015. The effect of small oligomeric protein aggregates on the immunogenicity of intravenous and subcutaneous administered antibodies. J Pharm Sci. 104(11):3691–702.
   PubMed Web of Science ®Google Scholar
• Ferguson M, Risi G, Davis M, Sheldon E, Baron M, Li P, Madariaga M, Fries L, Godeaux O, Vaughn D. 2012. Safety and long-term humoral immune response in adults after vaccination with an H1N1 2009 pandemic influenza vaccine with or without AS03 adjuvant. J Infect Dis. 205(5):733–44.
   PubMed Web of Science ®Google Scholar
• Fink SL, Cookson BT. 2005. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 73(4):1907–16.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D, Kupke A, Mair C, Makinson R, Sheridan J, Rohde C, et al. 2020a. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 20(7):816–26.
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, Bellamy D, Bibi S, Bittaye M, Clutterbuck EA, et al. 2020b. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 396(10249):467–78.
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Barenholz Y. 2003. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin Pharmacokinet. 42(5):419–36.
   PubMed Web of Science ®Google Scholar
• Gaitonde P, Peng A, Straubinger RM, Bankert RB, Balu-Iyer SV. 2012. Downregulation of CD40 signal and induction of TGF-beta by phosphatidylinositol mediates reduction in immunogenicity against recombinant human factor VIII. J Pharm Sci. 101(1):48–55.
   PubMed Web of Science ®Google Scholar
• Gallie DR. 1991. The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency. Genes Dev. 5(11):2108–16.
   PubMed Web of Science ®Google Scholar
• Garcon N, Vaughn DW, Didierlaurent AM. 2012. Development and evaluation of AS03, an adjuvant system containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines. 11(3):349–66.
   PubMed Web of Science ®Google Scholar
• Gordon DL, Sajkov D, Woodman RJ, Honda-Okubo Y, Cox MM, Heinzel S, Petrovsky N. 2012. Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax polysaccharide adjuvant. Vaccine. 30(36):5407–16.
   PubMed Web of Science ®Google Scholar
• Graham BS. 2020. Rapid COVID-19 vaccine development. Science. 368(6494):945–46.
   PubMed Web of Science ®Google Scholar
• Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD. 2021. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies.
   Google Scholar
• Guo L, Ren L, Yang S, Xiao M, Chang YF, Yang, F, Dela Cruz CS, Wang Y, Wu C, Xiao Y, et al. 2020. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 71(15):778–85.
   PubMed Web of Science ®Google Scholar
• Habrant D, Peuziat P, Colombani T, Dallet L, Gehin J, Goudeau E, Evrard B, Lambert O, Haudebourg T, Pitard B. 2016. Design of ionizable lipids to overcome the limiting step of endosomal escape: application in the intracellular delivery of mRNA, DNA, and siRNA. J Med Chem. 59(7):3046–62.
   PubMed Web of Science ®Google Scholar
• Hafez IM, Maurer N, Cullis PR. 2001. On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids. Gene Ther. 8(15):1188–96.
   PubMed Web of Science ®Google Scholar
• Hartmann G, Krieg AM. 2000. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol. 164(2):944–53.
   PubMed Web of Science ®Google Scholar
• Hendrickx R, Stichling N, Koelen J, Kuryk L, Lipiec A, Greber UF. 2014. Innate immunity to adenovirus. Hum Gene Ther. 25(4):265–84.
   PubMed Web of Science ®Google Scholar
• Ho JC, Chan KN, Hu WH, Lam WK, Zheng L, Tipoe GL, Sun J, Leung R, Tsang KW. 2001. The effect of aging on nasal mucociliary clearance, beat frequency, and ultrastructure of respiratory cilia. Am J Respir Crit Care Med. 163(4):983–88.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, et al. 2020. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 181(2):271–80 e8.
   PubMed Web of Science ®Google Scholar
• Holtkamp S, Kreiter S, Selmi A, Simon P, Koslowski M, Huber C, Tureci O, Sahin U. 2006. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood. 108(13):4009–17.
   PubMed Web of Science ®Google Scholar
• Honda-Okubo Y, Barnard D, Ong CH, Peng BH, Tseng CT, Petrovsky N. 2015. Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology. J Virol. 89(6):2995–3007.
   PubMed Web of Science ®Google Scholar
• Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, Lei HY. 2005. An interferon-gamma-related cytokine storm in SARS patients. J Med Virol. 75(2):185–94.
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Yang Y. 2020. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol. 20(6):339–41.
   PubMed Web of Science ®Google Scholar
• J&J. 2021. Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial. Online: Johnson & Johnson Services, Inc.
   Google Scholar
• Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, Chappell JD, Denison MR, Stevens LJ, et al. 2020. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med. 383(20):1920–31.
   PubMed Web of Science ®Google Scholar
• Kashem SW, Haniffa M, Kaplan DH. 2017. Antigen-presenting cells in the skin. Annu Rev Immunol. 35:469–99.
   PubMed Web of Science ®Google Scholar
• Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, et al. 2020. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 83:2320–2332.
   PubMed Web of Science ®Google Scholar
• Kim E, Erdos G, Huang S, Kenniston TW, Balmert SC, Carey CD, Raj VS, Epperly MW, Klimstra WB, Haagmans BL, et al. 2020. Microneedle array delivered recombinant coronavirus vaccines: immunogenicity and rapid translational development. EBioMedicine. 55:102743.
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 89(4):422–34.
   PubMed Web of Science ®Google Scholar
• Kou Y, Xu Y, Zhao Z, Liu J, Wu Y, You Q, Wang L, Gao F, Cai L, Jiang C. 2017. Tissue plasminogen activator (tPA) signal sequence enhances immunogenicity of MVA-based vaccine against tuberculosis. Immunol Lett. 190:51–57.
   PubMed Web of Science ®Google Scholar
• Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G. 2001. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 31(7):2154–63.
   PubMed Web of Science ®Google Scholar
• Kupferschmidt K. 2021. Fast-spreading U.K. virus variant raises alarms. Science. 371(6524):9–10.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang L, Zhu T, Wu S, Feng L, Cheng P, Liu J, Wang J. 2018. Establishing China’s national standard for the recombinant adenovirus type 5 vector-based Ebola vaccine (Ad5-EBOV) virus titer. Hum Gene Ther Clin Dev. 29(4):226–32.
   PubMed Web of Science ®Google Scholar
• Liu A. Top vaccine players Sanofi, GSK win $2.1B Warp Speed funding for COVID-19 shot. 2020 July 31.
   Google Scholar
• Liu H, Jin L, Koh SB, Atanasov I, Schein S, Wu L, Zhou ZH. 2010. Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks. Science. 329(5995):1038–43.
   PubMed Web of Science ®Google Scholar
• Liu J, Liao X, Qian S, Yuan J, Wang F, Liu Y, Wang Z, Wang FS, Liu L, Zhang Z. 2020. Community transmission of severe acute respiratory syndrome Coronavirus 2, Shenzhen, China, 2020. Emerg Infect Dis. 26(6):1320–23.
   PubMed Web of Science ®Google Scholar
• Liu L, Wei Q, Lin Q, Fang J, Wang H, Kwok H, Tang H, Nishiura K, Peng J, Tan Z, et al. 2019. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight. 2019 Feb 21; 4(4): e123158.
   Web of Science ®Google Scholar
• Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, et al. 2020. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 396(10255):887–97.
   PubMed Web of Science ®Google Scholar
• Love KT, Mahon KP, Levins CG, Whitehead KA, Querbes W, Dorkin JR, Qin J, Cantley W, Qin LL, Racie T, et al. 2010. Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A. 107(5):1864–69.
   PubMed Web of Science ®Google Scholar
• Martines RB, Ritter JM, Matkovic E, Gary J, Bollweg BC, Bullock H, Goldsmith CS, Silva-Flannery L, Seixas JN, Reagan-Steiner S, et al. 2020. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States. Emerg Infect Dis. 26(9):2005–15.
   PubMed Web of Science ®Google Scholar
• Mason RJ. 2020. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020 Apr 16;55(4):2000607. doi:10.1183/13993003.00607-2020.
   PubMed Web of Science ®Google Scholar
• Mercado NB, Zahn R, Wegmann F, Loos C, Chandrashekar A, Yu J, Liu J, Peter L, McMahan K, Tostanoski LH, et al. 2020. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 586(7830):583–88.
   PubMed Web of Science ®Google Scholar
• Merck. 2021. Merck Discontinues Development of SARS-CoV2/COVID-19 Vaccine Candidates; Continues Development of Two Investigational Therapeutic.
   Google Scholar
• Mistilis MJ, Joyce JC, Esser ES, Skountzou I, Compans RW, Bommarius AS, Prausnitz MR. 2017. Long-term stability of influenza vaccine in a dissolving microneedle patch. Drug Deliv Transl Res. 7(2):195–205.
   PubMed Web of Science ®Google Scholar
• ModernaTX. 2020. A study to evaluate efficacy, safety, and immunogenicity of mRNA-1273 vaccine in adults aged 18 years and older to prevent COVID-19. ClinicalTrialsGov.
   Google Scholar
• Mui BL, Tam YK, Jayaraman M, Ansell SM, Du X, Tam YY, Lin PJ, Chen S, Narayanannair JK, Rajeev KG, et al. 2013. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucleic Acids. 2:e139.
   PubMedGoogle Scholar
• Muik A, Wallisch A-K, Sänger B, Swanson KA, Mühl J, Chen W, Cai H, Sarkar R, Türeci Ö, Dormitzer PR, et al. 2021. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera. 2021.01.18.426984.
   Google Scholar
• Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, et al. 2020. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 586(7830):589–93.
   PubMed Web of Science ®Google Scholar
• Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, Nakagawa S, Nakanishi M, Tanaka K, Mayumi T. 1999. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J Control Release. 61(1–2):233–40.
   PubMed Web of Science ®Google Scholar
• NatureBiotechnology. 2021. AstraZeneca joins Russia to boost coronavirus vaccine. Nat Biotechnol. 39(1):11.
   PubMed Web of Science ®Google Scholar
• Naz A, Shahid F, Butt TT, Awan FM, Ali A, Malik A. 2020. Designing multi-epitope vaccines to combat emerging Coronavirus disease 2019 (COVID-19) by employing immuno-informatics approach. Front Immunol. 11:1663.
   PubMed Web of Science ®Google Scholar
• Ni L, Cheng M-L, Zhao H, Feng Y, Liu J, Ye F, Ye Q, Zhu G, Li X, Wang P, et al. 2020a. Impaired cellular immunity to SARS-CoV-2 in severe COVID-19 patients. medRxiv. 2020.08.10.20171371.
   Google Scholar
• Ni L, Ye F, Cheng ML, Feng Y, Deng YQ, Zhao H, Wei P, Ge J, Gou M, Li X, et al. 2020b. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity. 52(6):971–77 e3.
   PubMed Web of Science ®Google Scholar
• Nie Y, Wang G, Shi X, Zhang H, Qiu Y, He Z, Wang W, Lian G, Yin X, Du L, et al. 2004. Neutralizing antibodies in patients with severe acute respiratory syndrome-associated coronavirus infection. J Infect Dis. 190(6):1119–26.
   PubMed Web of Science ®Google Scholar
• Novavax. 2021. Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial. Online: Novavax, Inc.
   Google Scholar
• Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, Guo L, Guo R, Chen T, Hu J, et al. 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 11(1):1620.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. 2018. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 17(4):261–79.
   PubMed Web of Science ®Google Scholar
• Pastorino B, Touret F, Gilles M, De Lamballerie X, Charrel RN. 2020. Prolonged infectivity of SARS-CoV-2 in fomites. Emerg Infect Dis. 26(9):2256–2257.
   Web of Science ®Google Scholar
• Petrovsky N, Cooper PD. 2015. Advax, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety. Vaccine. 33(44):5920–26.
   PubMed Web of Science ®Google Scholar
• Pisal DS, Kosloski MP, Middaugh CR, Bankert RB, Balu-Iyer SV. 2012. Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice. J Pharm Sci. 101(6):2055–65.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, et al. 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 383(27):2603–15.
   PubMed Web of Science ®Google Scholar
• Polak SB, Van Gool IC, Cohen D, Von Der Thusen JH, Van Paassen J. 2020. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. 383: 2603–2615.
   PubMed Web of Science ®Google Scholar
• Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, et al. 2020. Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 71(15):762–68.
   PubMed Web of Science ®Google Scholar
• Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, Voysey M, Aley PK, Angus B, Babbage G, et al. 2021. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 396(10267):1979–93.
   PubMed Web of Science ®Google Scholar
• Randomized, Double Blind, Parallel Placebo Controlled, 2020. Phase III Clinical Trial to Evaluate the Safety and Protective Efficacy of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 18 Years and above Wuhan Institute of Biological Products co., LTD. at http://www.chictr.org.cn/hvshowproject.aspx?id=43780
   Google Scholar
• Richmond P, Hatchuel L, Dong M, Ma B, Hu B, Smolenov I, Li P, Liang P, Han HH, Liang J, et al. 2020. A first-in-human evaluation of the safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19 in healthy adults; a phase 1, randomised, double-blind, placebo-controlled trial. medRxiv. 2020.12.03.20243709.
   Google Scholar
• Roberts CJ. 2007. Non-native protein aggregation kinetics. Biotechnol Bioeng. 98(5):927–38.
   PubMed Web of Science ®Google Scholar
• Roman F, Clement F, Dewe W, Walravens K, Maes C, Willekens J, De Boever F, Hanon E, Leroux-Roels G. 2011. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol. 18(5):835–43.
   PubMedGoogle Scholar
• Rosenberg AS. 2006. Effects of protein aggregates: an immunologic perspective. Aaps J. 8(3):E501–7.
   PubMed Web of Science ®Google Scholar
• Ruan Q, Yang K, Wang W, Jiang L, Song J. 2020. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46(5):846–48.
   PubMed Web of Science ®Google Scholar
• Saade F, Honda-Okubo Y, Trec S, Petrovsky N. 2013. A novel hepatitis B vaccine containing Advax, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. Vaccine. 31(15):1999–2007.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Le Gars M, Shukarev G, Heerwegh D, Truyers C, De Groot AM, Stoop J, Tete S, Van Damme W, Leroux-Roels I, et al. 2021. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021 Jan 13;NEJMoa2034201. doi:10.1056/NEJMoa2034201
   Web of Science ®Google Scholar
• Sahin U, Kariko K, Tureci O. 2014. mRNA-based therapeutics–developing a new class of drugs. Nat Rev Drug Discov. 13(10):759–80.
   PubMed Web of Science ®Google Scholar
• Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, et al. 2020. Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine. medRxiv. 2020.07.17.20140533.
   Google Scholar
• Sarkar B, Ullah MA, Araf Y, Rahman MS. 2020. Engineering a novel subunit vaccine against SARS-CoV-2 by exploring immunoinformatics approach. Inform Med Unlocked. 21:100478.
   PubMedGoogle Scholar
• Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. 2008. Safety of MF59 adjuvant. Vaccine. 26(26):3209–22.
   PubMed Web of Science ®Google Scholar
• Singh M, Ugozzoli M, Kazzaz J, Chesko J, Soenawan E, Mannucci D, Titta F, Contorni M, Volpini G, Del Guidice G, et al. 2006. A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine. 24(10):1680–86.
   PubMed Web of Science ®Google Scholar
• Stone CA Jr., Liu Y, Relling MV, Krantz MS, Pratt AL, Abreo A, Hemler JA, Phillips EJ. 2019. Immediate hypersensitivity to polyethylene glycols and polysorbates: more common than we have recognized. J Allergy Clin Immunol Pract. 7(5):1533–40 e8.
   PubMed Web of Science ®Google Scholar
• Tay MZ, Poh CM, Renia L, MacAry PA, Ng LFP. 2020. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 20(6):363–74.
   PubMed Web of Science ®Google Scholar
• Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J, Doolabh D, Pillay S, San EJ, Msomi N, et al. 2020. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv. 2020.12.21.20248640.
   Google Scholar
• Teigler JE, Kagan JC, Barouch DH. 2014. Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity. J Virol. 88(18):10354–63.
   PubMed Web of Science ®Google Scholar
• Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeuchi Y, Weiss RA. 2005. Longitudinally profiling neutralizing antibody response to SARS coronavirus with pseudotypes. Emerg Infect Dis. 11(3):411–16.
   PubMed Web of Science ®Google Scholar
• Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, Van De Sandt CE, Jia X, Nicholson S, Catton M, Cowie B, et al. 2020. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 26(4):453–55.
   PubMed Web of Science ®Google Scholar
• Tian J-H, Patel N, Haupt R, Zhou H, Weston S, Hammond H, Lague J, Portnoff AD, Norton J, Guebre-Xabier M, et al. 2020a. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice. bioRxiv. 2020.06.29.178509.
   Google Scholar
• Tian S, Hu W, Niu L, Liu H, Xu H, Xiao S-Y. 2020b. Pulmonary pathology of early-phase 2019 novel Coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thoracic Oncol. 15(5):700–04.
   PubMed Web of Science ®Google Scholar
• University W. Oxford Covid-19 vaccine trial results. Online: University of the Witwatersrand, Johannesburg; 2021.
   Google Scholar
• Van Doremalen N, Haddock E, Feldmann F, Meade-White K, Bushmaker T, Fischer RJ, Okumura A, Hanley PW, Saturday G, Edwards NJ, et al. 2020. A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. Sci Adv. 6(24):eaba8399.
   PubMed Web of Science ®Google Scholar
• Vasques Nonaka CK, Miranda Franco M, Gräf T, Almeida Mendes AV, Santana de Aguiar R, Giovanetti M, Solano de Freitas Souza B. 2021. Genomic evidence of a Sars-Cov-2 reinfection case with E484K spike mutation in Brazil.
   Google Scholar
• Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P, Angus B, Bailie V, Barnabas S, Bhorat Q, et al. 2021a. Single dose administration, and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine. The Lancet. 397:37.
   Google Scholar
• Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, et al. 2021b. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 397(10269):99–111.
   PubMed Web of Science ®Google Scholar
• Wack A, Baudner BC, Hilbert AK, Manini I, Nuti S, Tavarini S, Scheffczik H, Ugozzoli M, Singh M, Kazzaz J, et al. 2008. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine. 26(4):552–61.
   PubMed Web of Science ®Google Scholar
• Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. 2020. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 181(2):281–92 e6.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck R, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. 2020a. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study.
   Google Scholar
• Walsh EE, Frenck RW Jr., Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, et al. 2020b. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 383(25):2439–50.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang L, Kuwahara K, Li L, Liu Z, Li T, Zhu H, Liu J, Xu Y, Xie J, et al. 2016a. Immunodominant SARS coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect Dis. 2(5):361–76.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhang L, Kuwahara K, Li L, Liu Z, Li T, Zhu H, Liu J, Xu Y, Xie J, et al. 2016b. Immunodominant SARS Coronavirus epitopes in humans elicited both enhancing and neutralizing effects on infection in non-human primates. ACS Infect Dis. 2(5):361–76.
   PubMed Web of Science ®Google Scholar
• Wang SF, Tseng SP, Yen CH, Yang JY, Tsao CH, Shen CW, Chen KH, Liu FT, Liu WT, Chen YM, et al. 2014. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. Biochem Biophys Res Commun. 451(2):208–14.
   PubMed Web of Science ®Google Scholar
• Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, Schaefer-Babajew D, Cipolla M, Gaebler C, Lieberman JA, et al. 2021. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. bioRxiv. 2021.01.15.426911.
   Google Scholar
• Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JCC, Muecksch F, Rutkowska M, Hoffmann HH, Michailidis E, et al. 2020. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 9. doi:10.7554/eLife.61312
   PubMed Web of Science ®Google Scholar
• WHO. 2020. Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. WHO.
   Google Scholar
• Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. 2020. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus disease 2019 (COVID-19): a review. JAMA. 324(8):782–93.
   PubMed Web of Science ®Google Scholar
• Williams K, Bastian AR, Feldman RA, Omoruyi E, De Paepe E, Hendriks J, Van Zeeburg H, Godeaux O, Langedijk JPM, Schuitemaker H, et al. 2020. Phase 1 safety and immunogenicity study of a respiratory syncytial virus vaccine with an adenovirus 26 vector encoding prefusion F (Ad26.RSV.preF) in adults aged >/=60 Years. J Infect Dis. 222(6):979–88.
   PubMed Web of Science ®Google Scholar
• Wilson JM. 2009. Lessons learned from the gene therapy trial for ornithine transcarbamylase deficiency. Mol Genet Metab. 96(4):151–57.
   PubMed Web of Science ®Google Scholar
• Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS. 2020. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 367(6483):1260–63.
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. 2020. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China. Jama. 323(13):1239.
   PubMed Web of Science ®Google Scholar
• Xia J, Tong J, Liu M, Shen Y, Guo D. 2020. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. J Med Virol. 92(6):589–94.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, et al. 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 8(4):420–22.
   PubMed Web of Science ®Google Scholar
• Yahalom-Ronen Y, Tamir H, Melamed S, Politi B, Shifman O, Achdout H, Vitner EB, Israeli O, Milrot E, Stein D, et al. 2020. A single dose of recombinant VSV-G-spike vaccine provides protection against SARS-CoV-2 challenge. Nat Commun. 11(1):6402.
   PubMed Web of Science ®Google Scholar
• Yang S, Li Y, Dai L, Wang J, He P, Li C, Fang X, Wang C, Zhao X, Huang E, et al. 2020. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD protein vaccine against COVID-19 in adults: pooled analysis of two randomized, double-blind, placebo-controlled, phase 1 and 2 trials. medRxiv. 2020.12.20.20248602.
   Google Scholar
• Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, Shim CK, Kim DD. 2007. Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm. 338(1–2):317–26.
   PubMed Web of Science ®Google Scholar
• Zhang BN, Wang Q, Liu T, Dou SQ, Qi X, Jiang H, Qi BX, Zhang B, Zhou QJ. 2020a. A special on epidemic prevention and control: analysis on expression of 2019-nCoV related ACE2 and TMPRSS2 in eye tissues. Zhonghua Yan Ke Za Zhi. 56(6):438–46.
   PubMedGoogle Scholar
• Zhang H, Zhou P, Wei Y, Yue H, Wang Y, Hu M, Zhang S, Cao T, Yang C, Li M, et al. 2020b. Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19. Ann Intern Med. 172(9):629–32.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen X, Chen L, Deng C, Zou X, Liu W, Yu H, Chen B, Sun X. 2020c. The evidence of SARS-CoV-2 infection on ocular surface. Ocul Surf. 18(3):360–62.
   PubMed Web of Science ®Google Scholar
• Zheng HY, Zhang M, Yang CX, Zhang N, Wang XC, Yang XP, Dong XQ, Zheng YT. 2020. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol. 17(5):541–43.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang CL, et al. 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579(7798):270–73.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Guan XH, Li YH, Huang JY, Jiang T, Hou LH, Li JX, Yang BF, Wang L, Wang WJ, et al. 2020. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 396(10249):479–88.
   PubMed Web of Science ®Google Scholar
• Zhu FC, Hou LH, Li JX, Wu SP, Liu P, Zhang GR, Hu YM, Meng FY, Xu JJ, Tang R, et al. 2015. Safety and immunogenicity of a novel recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in China: preliminary report of a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet. 385(9984):2272–79.
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Ma Y, Wang C, Hai L, Yan C, Zhang Y, Liu F, Cai L. 2012. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: role of lymphatic trafficking and biodistribution. J Control Release. 159(1):135–42.
   PubMed Web of Science ®Google Scholar
• Zimmermann P, Curtis N. 2020. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. Arch Dis Child. doi:10.1136/archdischild-2020-320338
   Web of Science ®Google Scholar